a median of 36 months in group A and 10 months in group AN (p = 0.06); a significant impairment of renal function was recorded in patients of AN group with respect to those of group A. Finally, 13/25 (52 %) patients of group A and 10/16 (62.5 %) patients of group AN died due to ACC-related causes. No differences in survival times were noted (p = 0.3). Conclusion Our study suggests that adjunctive nephrectomy does not modify the oncologic results of adrenalectomy in the treatment of stage II ACC in terms of recurrence-free and overall survival. Thus, when there are no signs of ACC local invasion, surgeon should make every effort to preserve the kidney.
Introduction
Adrenocortical carcinoma (ACC) is a rare malignancy, accounting annually for 0.02 % of all cancers with an incidence of one to two cases per 1.7 million population [1] . It has a bimodal distribution, with a first peak in children less than 5 years old and a second in adults in their forties-fifties. ACC is slightly more common in women than men [2] .
The 5-year survival remains poor and surgery is the only potentially curative treatment [3, 4] ; thus, the choice of the surgical strategy is crucial for patient's outcome. Open adrenalectomy is the standard treatment even if laparoscopy has been proposed recently in the treatment of stage I and II ACC [3, 5, 6] . When ACC is diagnosed in advanced stage, surgery is extensive implying additional procedures beyond adrenalectomy, such as nephrectomy, resection of pancreas tail, partial hepatectomy, or resection of diaphragm due to tumor spreading. Some authors suggested that extensive surgery may improve patient's survival [1, 3, 7, 8] .
Abstract
Purpose To evaluate if including nephrectomy in the standard surgical approach to stage II adrenocortical cancer (i.e., adrenalectomy) might modify oncologic outcome of patients. Methods We performed a retrospective analysis involving 41 patients with stage II adrenocortical cancer (ACC) who had undergone radical surgery. Patients were divided into two groups according to the surgical procedure: group A = radical adrenalectomy alone, group AN = radical adrenalectomy + radical nephrectomy. Oncologic effectiveness of the procedures was tested comparing the recurrence-free and overall survival of patients of A vs AN groups. Results The group A consisted of 25 patients and group AN of 16 patients. No differences were noted between the two groups in terms of demographic data and ACC characteristics. During follow-up, 15/25 (60 %) patients of group A vs 14/16 (87.5 %) patients of group AN experienced a recurrence, after Controversy does exist on the need to remove the kidney even when not macroscopically involved. Many years ago, some authors advocated that nephrectomy would help to decrease the high recurrence rate of ACC, because it would allow wide operative margins and avoid violating the tumor anatomic space, but this opinion has not yet been validated by clinical studies [9] . To date, little is known regarding the need for systematic, en bloc nephrectomy for ACC and the impact of concomitant nephrectomy on patient outcome remains to be clarified.
The aim of the present study was to review retrospectively the ACC database of our center (partaking in the European Network for the Study of Adrenal Tumors-ENS@T) to evaluate if including nephrectomy in the surgical approach to stage II ACC might modify the patient outcome.
Methods

ACC database of the San Luigi Hospital-Orbassano
The ACC database was established in 2001 with the development of a structured data form to collect comprehensive information of all patients with ACC who were referred at our center. Since 2001, all newly diagnosed patients were registered and followed proactively. All data were obtained by reviewing patients' histories, discharge summaries, medical records, and source documents. Data were retrieved by trained medical personnel using specifically tailored data forms. All patients provided written informed consent. For the purpose of this study, data of patients referred between January 1996 and December 2012 were considered. We included patients who underwent radical surgery either at our center or at other institutions. Follow-up for this study was closed in December 2013.
Patient cohort
Patients had to meet the following inclusion criteria: age of 18 years or older, stage II ACC according to the European Network for the Study of Adrenal Tumors (ENS@T) staging system (tumor >5 cm in size without infiltration of neighboring structures, including kidney, positive lymph nodes, thrombus in vena cava, or distant metastasis) [10] and availability of complete follow-up information until death or end of the study period. All histologic diagnoses were confirmed according to the Weiss criteria by experienced pathologists at our center who revised all diagnoses made in other institutions [11, 12] . Exclusion criteria were laparoscopic adrenalectomy, incomplete tumor staging, extensive surgical approach beyond adrenalectomy plus nephrectomy (resection of pancreas tail, partial hepatectomy, etc.), macroscopically incomplete resection, tumor capsule violation, concomitant cancers within the previous 5 years, and clinically significant concomitant diseases. Complete resection was defined as no evidence of residual disease on the basis of surgical reports, histopathological analysis, and postoperative imaging.
Follow-up visits, which included imaging of the chest and abdomen, were performed every 3-6 months until either disease progression occurred or the study period ended. The first post-operative CT was performed within one month following surgery. Renal function was monitored using serum creatinine and eGFR (MDRD formula) and classified according to K/DOQI clinical practice guidelines for chronic kidney disease [13] .
For the purpose of this analysis, disease recurrence was diagnosed on the basis of radiologic evidence of a new lesion during follow-up. Recurrence was defined as local when involving the operative site or regional lymph nodes, peritoneal when there was evidence of abdominal carcinomatosis, or distant. Adjuvant treatment following complete tumor removal and treatment of the recurrence were recorded.
Of 101 patients with stage II ACC identified, 41 met all entry criteria and were considered for analyses ( Fig. 1 ). Patients were divided into two groups according to the surgical procedure: group A consisted of patients treated with radical adrenalectomy alone, while group AN consisted of patients treated with radical adrenalectomy + radical nephrectomy. The surgical approach was based on surgeon preference and expertise and was not dictated by evidence of kidney involvement by ACC. Nephrectomy was done because of a supposed advantage of the completeness of surgery, or to facilitate tumor removal, or due to renal pedicle injury during adrenalectomy. 
Statistical analysis
All statistical analyses were performed with Statistica software (StatSoft ® ). Rates and proportions were calculated for categorical data and medians and ranges for continuous data. Differences in continuous variables were analyzed by means of the two-tailed Mann-Whitney U test. For categorical variables, differences were analyzed by means of the Chi-square test. Survival curves were computed according to the Kaplan-Meier method and were compared by means of the log-rank test.
Multivariate models were fitted to the data, in which age, tumor size, and Weiss score were included as covariates together with treatment group (adrenalectomy alone vs adrenalectomy + nephrectomy). This analysis was used to assess the predictive role of the treatment (adrenalectomy vs adrenalectomy + nephrectomy) and of clinical and pathological variables on disease recurrence. All reported p values are two-sided. p values <0.05 were considered statistically significant.
Study end-points
The primary end point of the study was to evaluate the oncologic effectiveness of concomitant nephrectomy comparing the recurrence-free survival (RFS) of patients treated with adrenalectomy alone (group A) vs adrenalectomy + nephrectomy (group AN). Secondary outcome measures were differences between the two groups in terms of overall survival (OS). RFS was measured from the date of surgery to the date of recurrence; patients who did not have a relapse were censored at the date of the last followup visit. OS was measured from the date of surgery to the date of death, or the date of the last follow-up visit.
Results
The group A consisted of 25 patients and group AN of 16 patients. No differences were noted between the two groups in terms of demographic data, ACC characteristics, and clinical presentation (Table 1) .
In 13 patients of group A (52 %) and 9 (60 %) of group AN, tumor involved right gland (p = 0.6). Mean size of right vs left tumor was 11.1 cm vs 11.0 cm (p = 0.99) in group A and 11.1 vs 13 cm in group AN (p = 0.91); no differences in terms of size of the tumor of the right gland (group A vs group AN) were noted (p = 0.99).
As far as surgical details are concerned, all patients were treated with an anterior transperitoneal approach. In all cases of Group A, perinephric fat of the upper pole of the kidney was removed with the adrenal gland while in patients of group AN kidney and the perirenal space limited by the Gerota's fascia were removed. The median followup duration of the whole cohort was 36 months . The median follow-up after surgery was 44 months (range 11-213) in group A and 31 months (range 8-156) in group AN. After adrenalectomy, 14 patients (56 %) of group A and 12 patients (75 %) of group AN were treated adjuvantly with mitotane (p = 0.2).
During follow-up, 15 out of 25 (60 %) patients of group A vs 14 out of 16 (87.5 %) patients of group AN experienced a recurrence: local recurrences were recorded in 5 and 3 patients of group A vs AN, respectively. Distant recurrences were observed in 11 and 10 patients, respectively. Median recurrence-free survival was 36 months in group A and 10 months in group AN and did not significantly differ according to the log-rank test (p = 0.06). Kaplan-Meier survival curves of the two groups are shown in Fig. 2 . There were no major differences in the management of recurrences between the two groups: repeat surgery followed by mitotane or cytotoxic chemotherapy were performed in 10 patients of A group and 9 patients of group AN; medical therapy alone in 4 and 4 patients, respectively; other treatments were used in the remainders.
During follow-up, no patients of group A vs 3 out 16 (18 %) patients of AN group (p = 0.02) experienced a stage migration according to KDOQI. During follow-up, 13 out of 25 (52 %) patients of group A and 10 out of 16 (62.5 %) patients of group AN died due to ACC-related causes. Median survival time was 48 months in group A and 36 months in group AN, respectively. This difference did not reach statistical significant (p = 0.3) at log-rank test. Figure 3 shows Kaplan-Meier survival curves of the two groups.
When considering multivariate models, none of the evaluated variables was found to be an independent prognostic factor of disease recurrence.
Discussion
It is well documented that surgery has a key role in the treatment of ACC. First, it represents the only chance for cure and a complete resection of the tumor and adrenal gland (R0 resection) is a strong predictor of long-term survival [3, 4, 8, 14, 15] . Second, when R0 resection is not possible due to extension of the disease, surgery has a role in tumor debulking as it may improve mass-related and hormone-related symptoms by reducing tumor mass and functional tissue even being not curative [3] . Finally, surgery is also important for treating resectable recurrence and distant metastases, as it may improve survival of selected patients with respect to chemotherapy alone [16, 17] .
Whilst nephrectomy is a well-established adjunctive therapy in case of kidney involvement for stage III ACC [3, 16] , the role of adding systematic nephrectomy to adrenalectomy for stage II ACC is unclear. Sometimes nephrectomy is required to facilitate the removal of large adrenal tumors or due to an incidental injury of renal pedicle during tumor dissection. In other cases, nephrectomy is performed because it is thought that it may improve the oncological results of adrenalectomy avoiding violation of tumor anatomic space [9] . This last hypothesis is plausible from the anatomical point of view. The adrenal gland develops adjacent to the kidney, and both are included in the perirenal space limited by the Gerota's fascia, the dense, collagenous, elastic connective tissue sheath that encompasses the kidney, the adrenal gland, and the surrounding fat [18, 19] . Furthermore, there is no complete fascial layer between the adrenal gland and the kidney, but rather only a thin perforate septum [19] . Thus, it is not difficult to imagine the spread of tumor cells through local extension, arterial or venous embolization. This spread could be not identified at the initial stages of the disease and could potentially justify the high rate of recurrence of ACC, suggesting the need of systematic nephrectomy during adrenalectomy. Similar considerations imprinted for many years the surgical approach to renal cell carcinoma, since adjunctive adrenalectomy has been considered for a long time a basic step during radical nephrectomy to improve oncologic results. Even if the role of adjunctive nephrectomy during adrenalectomy is supported by anatomical data and seems reasonable, no studies focused on this specific aspect.
In a sub-analysis of their retrospective study, Crucitti et al. reported on 129 patients treated for ACC and compared the survival of patients who received nephrectomy (23) with that of patients who did not (106) [20] . They did not find any statistical difference in terms of survival and concluded that the routine association of nephrectomy does not improve outcome. Similarly, in a retrospective evaluation of data of the French Association of Endocrine Surgery on 156 patients with ACC, no benefit from nephrectomy was observed at univariate analysis [21] . All these results should be interpreted with caution, however, mainly because of the lack of stratification for tumor stages.
To add a contribution in this field, we planned this retrospective study in which we evaluated the effects of adjunctive nephrectomy plus adrenalectomy in the ACC database of the San Luigi Hospital, one of the largest ACC monocentre databases. To limit bias due to different tumor stages, we considered only patients of the same stage. Since a stage I ACC rarely requires nephrectomy and the role of nephrectomy in case of renal involvement for stage III ACC is well established (when the kidney is involved), we selected only stage II ACC. To make homogeneous the population of the study, we included all patients with stage II ACC in whom adrenalectomy (or adrenalectomy + nephrectomy) was the only surgical treatment, excluding patients who were treated with more extensive surgery. From the surgical point of view, we compared two groups of patients in whom the surgical principles were respected (i.e., no tumor capsule violation, no residual disease at postoperative imaging). The two groups (A and AN) were well matched in terms of demographic and major prognostic factors, as far as tumor characteristics. Particularly, the size of the lesions and number of right tumors were well balanced in the two groups and we think that this is an important issue as the risk to damage renal vessels (and to do a nephrectomy) might increase with the size of the tumors excised, especially in the right side where renal vein is shorter. We chose RFS as the primary end point because we considered that RFS is a direct expression of the effectiveness of primary surgical therapy, whereas OS may be also influenced by subsequent, different treatments.
Overall, our data do not support the hypothesis that nephrectomy improves the oncologic results of adrenalectomy in patients with stage II ACC as confirmed by logrank test. The multivariate analysis demonstrated that the type of surgical treatment is not an independent prognostic factor. Conversely, we found that RFS was prolonged in patients treated with adrenalectomy only, even if the difference did not attain statistical significance. The trend toward a recurrence-free survival advantage may be explained by less surgery-induced immunosuppressive effects and the possibility to institute post-operative adjunctive treatments more rapidly [22, 23] . Pertinently, nephrectomy may limit the use of adjuvant or palliative chemotherapy, since patients with a single kidney are more prone to subsequent nephrotoxicity. As a matter of fact, we recorded some impairment of kidney function following surgery in group AN, at least measured as stage migration according to K/ DOQI, while no kidney function impairment was recorded in group A.
On the basis of these findings, we think that nephrectomy is not recommended in the absence of local extension and the kidney should be preserved in principle when a stage II ACC is extirpated. We think that it is a clinically important message and the results of this study could be transferable to urologists.
This study is not free of limitations. First, it is a retrospective study, thus offering a low level of evidence, even if data came from a prospectively maintained database. On the other hand, due to the rarity of the disease it is difficult to imagine a prospective randomized study. Second, the number of enrolled patients is rather low; however, the limited power of the study does not affect the meaning of our message, since a possible type II error may have hindered demonstration of a RFS advantage for adrenalectomy only, if any. Due to the same reason, multivariate analysis was not feasible for OS. Third, notwithstanding the two groups are fully comparable, the possibility that patients with some unmeasured characteristics were unevenly distributed between groups cannot be completely excluded. Fourth, the fact that different surgeons treated patients with ACC could introduce a bias and jeopardize the results of surgery as suggested by some authors [24] even if it reflects the real world context and makes the present results more reproducible for general practice.
Notwithstanding usual limitations inherent to a retrospective analysis and limited number or enrolled study, the results suggest that adjunctive nephrectomy does not modify the oncologic results of adrenalectomy in the treatment of stage II ACC in terms of recurrence-free and overall survival. Thus, when there are no signs of ACC local invasion, surgeon should make every effort to preserve the kidney.
